Technical Analysis for EGRX - Eagle Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 75.08 -0.31% -0.23
EGRX closed up 3.43 percent on Tuesday, June 19, 2018, on 1.88 times normal volume.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical EGRX trend table...

Date Alert Name Type % Chg
Jun 18 NR7 Range Contraction 3.12%
Jun 15 Slingshot Bullish Bullish Swing Setup 4.32%
Jun 15 Calm After Storm Range Contraction 4.32%
Jun 15 Upper Bollinger Band Walk Strength 4.32%
Jun 15 Overbought Stochastic Strength 4.32%
Jun 14 Upper Bollinger Band Walk Strength 2.23%
Jun 14 Overbought Stochastic Strength 2.23%
Jun 14 Upper Bollinger Band Touch Strength 2.23%
Jun 13 Upper Bollinger Band Walk Strength -2.01%
Jun 13 Above Upper BB Strength -2.01%

Older signals for EGRX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company markets EP-1101 (argatroban) to treat heparin-induced thrombocytopenia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; Ryanodex, a dantrolene to treat malignant hyperthermia; and EP-4104, a dantrolene that has completed a Phase I clinical study for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer; EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty; and EP-2101 (topotecan) to treat ovarian, cervical, and small-cell lung cancers. Eagle Pharmaceuticals, Inc. was founded in 2007 and is based in Woodcliff Lake, New Jersey.
Is EGRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 84.2
52 Week Low 45.05
Average Volume 240,834
200-Day Moving Average 58.2382
50-Day Moving Average 62.2826
20-Day Moving Average 69.664
10-Day Moving Average 72.493
Average True Range 3.06
ADX 41.74
+DI 27.96
-DI 9.38
Chandelier Exit (Long, 3 ATRs ) 68.14
Chandelier Exit (Short, 3 ATRs ) 73.33
Upper Bollinger Band 76.4337
Lower Bollinger Band 62.8943
Percent B (%b) 0.92
BandWidth 19.435289
MACD Line 3.3225
MACD Signal Line 3.2018
MACD Histogram 0.1207
Fundamentals Value
Market Cap 1.14 Billion
Num Shares 15.2 Million
EPS 5.96
Price-to-Earnings (P/E) Ratio 12.64
Price-to-Sales 3.34
Price-to-Book 4.96
PEG Ratio 0.95
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 80.65
Resistance 3 (R3) 80.20 77.97 79.76
Resistance 2 (R2) 77.97 76.61 78.20 79.46
Resistance 1 (R1) 76.64 75.77 77.31 77.09 79.17
Pivot Point 74.41 74.41 74.74 74.64 74.41
Support 1 (S1) 73.08 73.05 73.75 73.53 71.45
Support 2 (S2) 70.85 72.21 71.08 71.16
Support 3 (S3) 69.52 70.85 70.86
Support 4 (S4) 69.97